Cargando…

Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetes

AIMS/INTRODUCTION: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are used worldwide because of their multiple benefits for patients with type 2 diabetes. The purpose of this study was to determine the efficacy and safety of SGLT2i in patients with type 1 diabetes. MATERIALS AND METHODS: Patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiba, Koki, Nomoto, Hiroshi, Nakamura, Akinobu, Cho, Kyu Yong, Yamashita, Kumiko, Shibayama, Yui, Miya, Aika, Kameda, Hiraku, Kurihara, Yoshio, Aoki, Shin, Atsumi, Tatsuya, Miyoshi, Hideaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7858126/ https://www.ncbi.nlm.nih.gov/pubmed/32593203 http://dx.doi.org/10.1111/jdi.13335

Ejemplares similares

Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone
por: Cho, Kyu Yong, et al.
Publicado: (2020)

Impact of sodium–glucose cotransporter 2 inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease with normoalbuminuria
por: Nakamura, Akinobu, et al.
Publicado: (2020)

Protective effect of sodium–glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease and type 2 diabetes
por: Miyoshi, Hideaki, et al.
Publicado: (2019)

ODP190 Efficacy of Esaxerenone on Hypertensive Patients with Type 2 Diabetes or Those with Impaired Glucose Tolerance
por: Kuwabara, Saki, et al.
Publicado: (2022)

Log-linear relationship between endogenous insulin secretion and glycemic variability in patients with type 2 diabetes on continuous glucose monitoring
por: Miya, Aika, et al.
Publicado: (2021)

Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study)
por: Nomoto, Hiroshi, et al.
Publicado: (2022)

Gitelman's syndrome with hyperphosphatemia, effectively responding to single oral magnesium oxide administration: A case report
por: Miya, Aika, et al.
Publicado: (2019)

MON-492 A Case of Gitelman’s Syndrome with Hyperphosphatemia That Responded Effectively to Single Oral Administration of Magnesium Oxide
por: Miya, Aika, et al.
Publicado: (2019)

SAT-282 Hypothalamic Pituitary Adrenal Axis Hyperactivity in Db/db Mice
por: Kameda, Hiraku, et al.
Publicado: (2020)

Impaired insulin secretion predicting unstable glycemic variability and time below range in type 2 diabetes patients regardless of glycated hemoglobin or diabetes treatment
por: Miya, Aika, et al.
Publicado: (2020)

ODP338 Neuromedin B Receptor Antagonist Suppresses ACTH Secretion and Cell Proliferation in Human and Mouse Corticotroph Adenoma
por: Atsumi, Tatsuya, et al.
Publicado: (2022)

Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteopenia/osteoporosis
por: Miyoshi, Arina, et al.
Publicado: (2020)

Effect of switching from pioglitazone to the sodium glucose co‐transporter‐2 inhibitor dapagliflozin on body weight and metabolism‐related factors in patients with type 2 diabetes mellitus: An open‐label, prospective, randomized, parallel‐group comparison trial
por: Cho, Kyu Yong, et al.
Publicado: (2018)

Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study)
por: Nomoto, Hiroshi, et al.
Publicado: (2022)

The association between hypoglycemia and glycemic variability in elderly patients with type 2 diabetes: a prospective observational study
por: Handa, Takahisa, et al.
Publicado: (2021)

ODP332 Maternal Central Diabetes Insipidus Immediately after Delivery, Owing to Vasospasm of the Internal Carotid Artery
por: Yokozeki, Kei, et al.
Publicado: (2022)

ODP285 A Case of Encephalitis and Adrenal Insufficiency in a Patient With Panhypopituitarism After COVID-19 Vaccination
por: Yabe, Ichiro, et al.
Publicado: (2022)

Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin
por: Miya, Aika, et al.
Publicado: (2021)

Combination of alcohol and glucose consumption as a risk to induce reactive hypoglycemia
por: Oba‐Yamamoto, Chiho, et al.
Publicado: (2020)

ODP328 Longitudinal Multidisciplinary Approach for Cabergoline-Resistant Aggressive Prolactinoma Complicated by Multiple Endocrine Neoplasia Type 1
por: Furusawa, Sho, et al.
Publicado: (2022)

MON-483 Familial Dysalbuminemic Hyperthyroxinemia with False Hypercortisolemia
por: Chiba, Koki, et al.
Publicado: (2020)

ODP037 Effects of DHCR24 Inhibitor on Excessive Adrenal Steroidogenesis in db/db mouse
por: Kamigaki, Risa, et al.
Publicado: (2022)

SAT040 Administration Of A DHCR24 Inhibitor Reduces The Excessive Adrenal Steroidogenesis In db/db Mice Through Effects The Alteration Of Intracellular Cholesterol Metabolism
por: Kamigaki, Risa, et al.
Publicado: (2023)

Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Glucose Metabolism and Treatment Satisfaction in Patients with Type 2 Diabetes: Protocol for a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Comparison Study (The SWITCH-SEMA 1 Study)
por: Nomoto, Hiroshi, et al.
Publicado: (2021)

Case of fulminant type 1 diabetes induced by the anti‐programmed death‐ligand 1 antibody, avelumab
por: Shibayama, Yui, et al.
Publicado: (2019)

Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial
por: Takase, Takahiro, et al.
Publicado: (2018)

Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study
por: Oe, Yuki, et al.
Publicado: (2022)

Effect of the sodium–glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages
por: Takahashi, Kiyohiko, et al.
Publicado: (2018)

Impact of Glucose Loading on Variations in CD4(+) and CD8(+) T Cells in Japanese Participants with or without Type 2 Diabetes
por: Miya, Aika, et al.
Publicado: (2018)

Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: A randomized controlled trial of repaglinide vs sulfonylurea
por: Omori, Kazuno, et al.
Publicado: (2018)

Satisfaction of switching to combination therapy with lixisenatide and basal insulin in patients with type 2 diabetes receiving multiple daily insulin injection therapy: A randomized controlled trial
por: Miya, Aika, et al.
Publicado: (2017)

ODP279 A Case of Nephrogenic Diabetes Insipidus Diagnosed at an Advanced Age in a Female Patient with an AVPR2 Gene Mutation and Skewed×Inactivation
por: Nakata, Kento, et al.
Publicado: (2022)

Breakdown of Autonomously Functioning Thyroid Nodule Accompanied by Acromegaly After Octreotide Treatment
por: Nomoto, Hiroshi, et al.
Publicado: (2019)

The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3)
por: Kitao, Naoyuki, et al.
Publicado: (2017)

Acromegaly Cases Exhibiting Increased Growth Hormone Levels during Oral Glucose Loading with Preadministration of Dipeptidyl Peptidase-4 Inhibitor
por: Oba-Yamamoto, Chiho, et al.
Publicado: (2021)

Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes
por: Takahashi, Kiyohiko, et al.
Publicado: (2018)

Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study
por: Cho, Kyu Yong, et al.
Publicado: (2021)

SAT-271 Block and Replace Therapy Successfully Improved Symptoms in Recurrent Cyclic Cushing’s Disease
por: Kamigaki, Risa, et al.
Publicado: (2020)

MON-465 Novel Thyroid Hormone β Mutation L266s Causes Atrial Fibrillation & Cerebral Infarction
por: Ono, Wataru, et al.
Publicado: (2020)

Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis
por: Nomoto, Hiroshi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ijnfp4nl2dkr27d8poh5dj2ebc